STRUCTURED SALES MATERIAL 100% Capital Protected Deposit – Global Pharmaceuticals 1 December 2012 For Professional Investors Only Investment linked to a basket of US, European and Japanese Pharmaceutical stocks, providing the opportunity for annual returns of up to 5.00% over the first 4 years and exposure to the performance of the underlying stocks at the end of year 5. The investment is 100% capital protected at the Account Closing Date Product Summary Key Features Product Global Pharmaceuticals 1 - Deposit Deposit Taker Nomura Bank International plc („NBI‟), rated as A- by S&P  The Nomura Global Brands 1 (“the Deposit”) is linked to a basket of US, European and Japanese Pharmaceutical stocks  The Deposit provides investors with the potential for returns of 5.00% for each of the first 4 years, combined with participation in the performance of the underlying stocks at the Final Valuation Date.  The Deposit taker is Nomura Bank International plc (“the Issuer”), which is rated by S&P as A-, at the time of a publication  The Deposit is available in USD, GBP and has an investment term of 5 years, and is intended to be held for the entire period  The 100% Capital Protection only applies at Maturity Investment Term 5 years Currency Available in USD and GBP Underlying Assets GlaxoSmithKline Plc (GSK LN Equity) Johnson & Johnson (JNJ US Equity) Novartis AG (NOVN VX Equity) Abbott Laboratories (ABT US Equity) Takeda Pharmaceutical Co Ltd (4502 JT Equity) Key Dates Initial Valuation Date: 15 January 2013 Deposit Date: 22 January 2013 Final Valuation Date: 15 January 2018 Account Closing Date (Maturity): 22 January 2018 Investment Description  Conditional 5.00% Coupon Amount A 5 year investment linked to the performance of the stocks of GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Abbott Laboratories and Takeda Pharmaceutical Co Ltd Conditional Coupon Following each Conditional Coupon Observation Date, if the price of each underlying is greater than or equal to 105% of its Initial Valuation Level the Deposit will pay a coupon of 5.00%  Redemption Value 100% + Performance of the Worst Performing Asset (subject to minimum value of 100%) Your initial investment is made at a price of 100%, and there is potential on each of the 4 annual Conditional Coupon Observation Dates to receive a 5% coupon  Capital Risk 100% Capital Protected at the Account Closing Date. The Value of the deposit may be more or less than 100% prior to the Account Closing Date In addition to the potential for income, at the end of year 5, the investor will participate in the performance of the Worst Performing Asset. For example if GlaxoSmithKline Plc has returned +20% over the 5 year period and is the worst performing asset, the investor will receive 120% of their invested capital  In the worst case scenario at maturity, if all of the Underlying Assets have performed negatively. The investor will still have 100% of capital invested returned at the 5 year maturity Initial Valuation The level or price of each Underlying at the close Level of the Initial Valuation Date Final Valuation Level The level or price of each Underlying at the close of the Final Valuation Date Conditional Coupon Observation Dates 15 January 15 January 15 January 16 January Worst Performing Asset The Underlying Asset with the lowest Performance at the scheduled closing time on each Conditional Coupon Observation Date and the Final Valuation Date Performance (Final Valuation Level / Initial Valuation Level) - 1 Product Reference Global Pharmaceuticals 1 USD Deposit Global Pharmaceuticals 1 GBP Deposit 2014, 2015, 2016, 2017 Investor Returns at Account Closing Date Performance of Worst Performing Underlying at Maturity (Final / Initial Level) 140% 120% 100% 80% 60% 40% 20% 0% Redemption Amount at Maturity 140% 120% 100% 100% 100% 100% 100% 100% 100% Capital Protected Deposit – Global Pharmaceuticals 1 December 2012 The Underlying Assets GlaxoSmithKline Plc  GlaxoSmithKline PLC is a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart & circulatory disease, and cancer. 5 Year Performance 140 120 100 80 60 40 20 0 Dec-07 Dec-08 Johnson & Johnson  The Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world. Dec-11 Dec-12 Dec-11 Dec-12 Dec-11 Dec-12 Dec-11 Dec-12 Dec-11 Dec-12 100 80 60 40 20 0 Dec-07 Dec-08 Dec-09 Dec-10 5 Year Performance Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products. 120 100 80 60 40 20 0 Dec-07 Dec-08 Abbott Laboratories  Dec-10 120 Novartis AG  Dec-09 5 Year Performance Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors. Dec-09 Dec-10 5 Year Performance 140 120 100 80 60 40 20 0 Dec-07 Dec-08 Takeda Pharmaceutical Company Limited  Takeda Pharmaceutical Company Limited mainly manufactures and sells pharmaceuticals, food supplements, and chemical products like polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. Takeda Pharmaceutical researches, develops, and promotes the products through its related companies in the US, Europe, and Asia. Dec-09 Dec-10 5 Year Performance 120 100 80 60 40 20 0 Dec-07 Dec-08 Dec-09 Dec-10 Source for company descriptions and historical prices, Bloomberg, as of 11 December 2012. Charts are indexed at 100 starting on 11 December 2007 Past performance is no indication of future performance This publication has been issued by the Sales/Trading departments of Nomura International plc, in order to promote investment services and is provided without compensation. This document should not be considered an offer to buy or sell investments. We are not your designated investment adviser and this information is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and are capable of undertaking your own objective analysis of the investment and its suitability to meet your requirements. The information is based on sources we believe to be reliable, but we do not represent that it is accurate or complete. Any valuations contained herein are subject to change without notice. Nomura International plc and/or connected persons do not accept any liability whatsoever for any direct, incorrect or inconsequential loss arising from any use of the information or its content. Nomura International plc is authorised and regulated by the Financial Services Authority. 100% Capital Protected Deposit – Global Pharmaceuticals 1 Annual Observation Dates and the Final Valuation Date Month 12: Are all Underlying Assets at, or above 105% of their initial level? Deposit Returns 5.00% Coupon Yes No Month 24: Are all Underlying Assets at, or above 105% of their initial level? 5.00% Coupon Yes No Full Product Term is 5 years At Maturity, Month 60: This check is performed every 12 months for first 4 years Are all Underlying Assets at, or above 100% of their initial level? Yes Deposit redeems at: 100% capital + Performance of Worst Performing Asset No Deposit redeems at 100% of initial investment. i.e. the deposit is 100% Capital Protected at Maturity Nomura – Global Reach  Nomura Bank International plc is part of the Nomura Group. The ultimate parent company is Nomura Holdings, Inc. (“Nomura”)  Nomura is a leading global investment bank:  Full range of products supported by a global network of more than 35,000 employees in over 30 countries;  Nomura maintains a robust financial position and a healthy balance sheet. As at the end of June 2012, Nomura‟s Tier 1 ratio was 15.0%, and shareholders‟ equity of 2.1 trillion yen.  Listed on Tokyo, New York, and Singapore stock exchanges.  Stable and well diversified revenues across regions  The Deposit is issued by Nomura Bank International plc, and are NOT guaranteed by Nomura Holdings, Inc. or any other group company. Overview: Q1 2012/13 Net Revenue by Division Wholesale Banking JPY 121.9bn Retail JPY 82.7bn Asset Mgmt JPY 16.4bn Source: News Release: Nomura Reports First Quarter Financial Results, Nomura website: www.nomura.com as of July 2012. Structured Sales Contacts     Tel: Fax: Email: Web: +44 (0) 207 103 5773 +44 (0) 207 521 1561 UKStructuredSales@nomura.com www.nomura.com  Nomura International plc One Angel Lane London EC4R 3AB This publication has been issued by the Sales/Trading departments of Nomura International plc, in order to promote investment services and is provided without compensation. This document should not be considered an offer to buy or sell investments. We are not your designated investment adviser and this information is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and are capable of undertaking your own objective analysis of the investment and its suitability to meet your requirements. The information is based on sources we believe to be reliable, but we do not represent that it is accurate or complete. Any valuations contained herein are subject to change without notice. Nomura International plc and/or connected persons do not accept any liability whatsoever for any direct, incorrect or inconsequential loss arising from any use of the information or its content. Nomura International plc is authorised and regulated by the Financial Services Authority. 100% Capital Protected Deposit – Global Pharmaceuticals 1 December 2012 Disclaimer : This information has been issued by the Sales/Trading departments of Nomura International plc ("NIplc") and is made available to you by NIplc and/or its affiliates (collectively, "Nomura"), in order to promote investment services and is provided without compensation. This is not investment research as defined by the UK Financial Services Authority ("FSA"), nor is it research under the rules of the U.S. Self Regulatory Organizations of which Nomura is a member or under applicable rules in Hong Kong. Information contained herein is provided for informational purposes only, is intended solely for your use and may not be quoted, circulated or otherwise referred to without our express consent. This material contains indicative terms only, and should not be considered as an offer to buy or sell securities or other products discussed herein. Any prices, yields and opinions expressed are subject to change without notice. The information is based on sources we believe to be reliable, but we do not represent that it is accurate or complete. We are not your designated investment adviser and this information is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and are capable of undertaking your own objective analysis of the investment and its suitability to meet your requirements. It does not constitute a personal recommendation as defined by the FSA, or take into account the particular investment objectives, financial situations or needs of individual investors. Nomura and/or connected persons do not accept any liability whatsoever for any direct, indirect or consequential loss arising from any use of the information or its content. Nomura also may have acted as an underwriter of such securities or other products discussed in this material, and may currently be providing investment banking services to the issuers of such securities or products. Nomura and/or its officers, directors and employees, including persons, without limitation, involved in the preparation or issuance of this material may, from time to time, have long or short positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein, or related securities or derivatives. This material has been approved for distribution in the United Kingdom and European Union by NIplc, which is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange. It is not intended for retail clients. It is intended only for investors who are "eligible market counterparties" or "professional clients " as defined by the FSA, and may not, therefore, be redistributed to other classes of investors. Any securities described herein may not have been registered under the U.S. Securities Act of 1933, and, in such case, may not be offered or sold to U.S. investors unless they have been registered or sold in an exempted transaction. Nomura is the global marketing name of Nomura Holdings, Inc. (Tokyo) and its direct and indirect subsidiaries worldwide including Nomura International (Hong Kong) Limited, licensed and regulated by the Hong Kong Securities and Futures Commission, Nomura Securities International, Inc (New York), a member of FINRA, NYSE and SIPC and Nomura International plc (London), authorised and regulated by the Financial Services Authority (“FSA”) and member of the London Stock Exchange. Nomura manages conflicts identified through the following: their Chinese Wall, confidentiality and independence policies, maintenance of a Stop List and a Watch List, personal account dealing rules, policies and procedures for managing conflicts of interest arising from the allocation and pricing of securities and impartial investment research and disclosure to clients via client documentation. Disclosure information is available at http://www.nomura.com/research/. This factsheet is for information only and use by professional financial advisors only, and should not be considered a financial promotion. This information alone should not be relied on for making investment or purchasing decisions. Who Can Invest in the Deposit? The Deposit is available for purchase within the UK and offshore for the following three investor categories:  Qualified Professional Investors  Offshore Life Companies buying as principal  Corporate and Institutional clients buying as principal  Minimum Initial Investment per counterparty is GBP 50,000 or USD 50,000 Key Dates Initial Strike Date 15 January 2013 Deposit Date 22 January 2013 Final Valuation Date 15 January 2018 Account Closing Date 22 January 2018 Risks  Please bear in mind that investors are exposed to the credit risk of the Deposit taker. Any secondary market provided by Nomura International plc is subject to change and may be stopped without notice and investors may therefore be unable to sell or redeem the Deposit until their maturity. If the Deposit is redeemed early they may be redeemed at a level less than the amount originally invested. Structured Sales Contacts     Tel: Fax: Email: Web: +44 (0) 207 103 5773 +44 (0) 207 521 1561 UKStructuredSales@nomura.com www.nomura.com  Nomura International plc One Angel Lane London EC4R 3AB